CFG
36
12
BAX
38
2
CCL
68
6
EXPE
83
8
CVS
27
2
LOW
42
14
MA
60
5
PHM
44
4
UNH
42
6
ITW
45
2
VIX
41
-11
TSCO
42
4
MTCH
62
22
CHD
34
7
D
32
10
MMC
46
5
SLG
37
6
CLX
65
2
COP
36
2
ABT
54
4
CFG
36
12
BAX
38
2
CCL
68
6
EXPE
83
8
CVS
27
2
LOW
42
14
MA
60
5
PHM
44
4
UNH
42
6
ITW
45
2
VIX
41
-11
TSCO
42
4
MTCH
62
22
CHD
34
7
D
32
10
MMC
46
5
SLG
37
6
CLX
65
2
COP
36
2
ABT
54
4
Financhill
Back

Ascendis Pharma AS Quote, Financials, Valuation and Earnings

This Tech Company Grew 32,481%...

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
43

ASND
Ascendis Pharma AS

Last Price:
$136.20
Seasonality Move:
19.34%

7 Day Trial

ALL ACCESS PASS

$ 7

These 7 Stocks Will Be Magnificent in 2025

Get Your Copy of "These 7 Stocks Will Be Magnificent in 2025" Here.

Ascendis Pharma AS Price Quote

$136.20
-0.04 (-1.12%)
(Updated: December 21, 2024 at 5:15 AM ET)

Ascendis Pharma AS Key Stats

Sell
43
Ascendis Pharma AS (ASND) is a Sell
Day range:
$135.61 - $141.37
52-week range:
$111.09 - $161.00
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
21.92
P/B ratio:
0%
Volume:
632.7K
Avg. volume:
509.4K
1-year change:
12.45%
Market cap:
$8.1B
Revenue:
$288.8M
EPS:
$-8.11

How Much Does Ascendis Pharma AS Make?

Data Unavailable

Is Ascendis Pharma AS Growing As A Company?

Data Unavailable

Ascendis Pharma AS Stock Price Performance

What Is Ascendis Pharma AS 52-Week High & Low?

Ascendis Pharma AS Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Ascendis Pharma AS?

Data Unavailable

Is Ascendis Pharma AS Cash Flow Positive?

Data Unavailable

Ascendis Pharma AS Return On Invested Capital

Data Unavailable

Ascendis Pharma AS Earnings Date & Stock Price

Ascendis Pharma AS Competitors

  • Who Are Ascendis Pharma AS's Competitors?
    Below is a list of companies who compete with Ascendis Pharma AS or are related in some way:
    • Akari Therapeutics PLC (AKTX)
    • Biodexa Pharmaceuticals PLC (BDRX)
    • Evaxion Biotech AS (EVAX)
    • Novo Nordisk AS (NVO)
    • Trinity Biotech PLC (TRIB)

Ascendis Pharma AS Dividend Yield

Data Unavailable

Ascendis Pharma AS Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -15.93%
Revenue: 21.62% -17.39%

Analyst Recommendations

Buy Recommendations: 11
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 189.82
Upside from Last Price: 39.33%

Major Shareholders

Data Unavailable